Table 1.
Characteristics of patients with THRLBCL, compared with DLBCL-NOS and NLPHL, diagnosed in 2010–2015.
| Variable | THRLBCL N=622 |
DLBCL-NOS N=91,588 |
P a | NLPHL N=2,240 |
P a | ||||
|---|---|---|---|---|---|---|---|---|---|
| Age: | |||||||||
| Median | 58 | 68 | <.001 | 47 | <.001 | ||||
| IQR b | 42–70 | 57–77 | 33–60 | ||||||
| Sex, N (%) | |||||||||
| Male | 411 | (66.1) | 50,045 | (54.6) | <.001 | 1,437 | (64.2) | .37 | |
| Female | 211 | (33.9) | 41,543 | (45.4) | 803 | (35.8) | |||
| Male:female ratio | 1.9 | 1.2 | 1.8 | ||||||
| Race/ethnicity, N (%) | |||||||||
| White | 454 | (73.0) | 79,388 | (86.7) | <.001 | 1,566 | (69.9) | .51 | |
| Black | 144 | (23.2) | 7,067 | (7.7) | 574 | (25.6) | |||
| Asian / other | 24 | (3.8) | 5,133 | (5.6) | 100 | (4.5) | |||
| Comorbidity index, N (%) | |||||||||
| 0 | 500 | (80.4) | 66,338 | (72.4) | <.001 | 1,908 | (85.2) | .027 | |
| 1 | 88 | (14.1) | 16,780 | (18.3) | 244 | (10.9) | |||
| 2 | 24 | (3.9) | 4,905 | (5.4) | 68 | (3.0) | |||
| ≥3 | 10 | (1.6) | 3,565 | (3.9) | 20 | (0.9) | |||
| Stage, N (%) | |||||||||
| I/II | 118 | (19.0) | 40,560 | (44.3) | <.001 | 1,475 | (65.8) | <.001 | |
| III/IV or unrecorded c | 504 | (81.0) | 51,028 | (55.7) | 765 | (34.2) | |||
| B symptoms, N (%) | |||||||||
| Absent | 299 | (48.1) | 57,388 | (62.7) | <.001 | 1,776 | (79.3) | <.001 | |
| Present | 276 | (44.4) | 25,525 | (27.9) | 332 | (14.8) | |||
| Unrecorded | 47 | (7.6) | 8,675 | (9.5) | 132 | (5.9) | |||
| Primary site, N (%) | |||||||||
| Nodal | 590 | (94.9) | 59,975 | (65.5) | <.001 | 2,198 | (98.1) | <.001 | |
| Extranodal | 10 | (1.6) | 14,837 | (16.2) | 32 | (1.4) | |||
| High-risk extranodal | 22 | (3.5) | 16,776 | (18.3) | 10 | (0.4) | |||
| Reporting hospital, N (%) | |||||||||
| Academic/research | 292 | (46.9) | 37,240 | (40.7) | .001 | 933 | (41.7) | .018 | |
| Other | 330 | (53.1) | 54,348 | (59.3) | 1,307 | (58.3) | |||
| Chemotherapy, N (%) | |||||||||
| Administered | 558 | (89.7) | 76,083 | (83.1) | <.001 | 1,279 | (57.1) | <.001 | |
| Not administered or unrecorded c | 64 | (10.3) | 15,505 | (16.9) | 961 | (42.9) | |||
| Stem cell transplantation, N (%) | |||||||||
| Yes | 30 | (4.8) | 1,498 | (1.6) | <.001 | <10c | (<1.0) | <.001 | |
| No or unrecorded c | 592 | (95.2) | 90,090 | (98.4) | >2,220c | (>99.0) | |||
| R-IPI, N (%) | |||||||||
| Recorded, N (% total) | 105 | (17.0) | 10,610 | (11.6) | |||||
| Very good | 653 | (6.3) | .043 | ||||||
| Good | 43c | (41.0) | 4,669 | (45.0) | |||||
| Poor | 62 | (59.0) | 5,058 | (48.7) | |||||
IQR: interquartile range; R-IPI: revised International Prognostic Index
a
P value for univariate comparison with THRLBCL
b
age range was 18 to ≥90 years for all groups
c
categories combined or rounded to protect patients’ privacy (NCDB disallows cell sizes smaller than 10); stage was unrecorded in 2.8%, chemotherapy receipt in 1.4%, and transplantation in 0.7% of patients.